Introduction
============

Since the discovery of trace amine-associated receptors (TAARs) in 2001 ([@B13]; [@B15]), there has been a gradually growing interest in the therapeutic potential of this family of receptors. This interest has largely focused on the most well-characterized family member, TAAR1, and its potential as a novel target for pharmacotherapy of psychiatric disorders, in particular schizophrenia ([@B109]) and drug abuse ([@B105]), and more recently metabolic disorders ([@B107]). In this article, we will present evidence that leads us to propose that TAARs also comprise a potential therapeutic target for disorders associated with an environmentally induced hyper-reactive immune state. Recent review articles have thoroughly covered general ([@B105]) and human ([@B8]) TAAR pharmacology to which the reader is referred for more detailed background information. Here, we will focus our discussion on recent evidence that supports a role for TAARs in regulating immune cell functions, and also implicates changes in endogenous TAAR ligands in the etiology of dysfunctional immune responses at epithelial cell barrier layers, with a particular view toward the gastrointestinal tract, which has had the most focus up until now. From these studies, we will develop the hypothesis that TAARs are novel therapeutic targets for environmental hypersensitivity and other immunomodulatory disorders.

Evolution and Genetics of Human TAARs
=====================================

Compared to many other G protein-coupled receptors, TAARs show a quite pronounced species-dependent diversity due to a large number of species-specific duplications, deletions, and pseudogenizations. In mammals, each species' TAAR complement clusters together as single exon genes (with the exception of TAAR2 which contains two exons) on a single chromosome. Within the nine mammalian TAAR sub-families, there are two distinct clades comprising TAAR1--4 and TAAR5--9. TAAR1--4 are evolutionarily the oldest members, with TAAR1 the oldest and TAAR4 the second oldest ([@B80]; [@B38]), appear to be tuned to the detection of primary amines ([@B43]), and are under negative selection pressures ([@B38]). By contrast, TAAR5--9 are tuned toward tertiary amines ([@B43]) and are under strong positive selection pressures ([@B58]; [@B128]), with a variety of species-specific isoforms identified ([@B38]). Such positive selection pressures may indicate an evolutionary role in environmental adaptation responses, and indeed the TAAR expression profiles of at least some species may respond to habitat changes ([@B22]; [@B39]). Furthermore, with the notable exception of TAAR1, TAARs have also now been confirmed as a new family of receptors involved in olfaction, which respond to volatile signaling molecules associated with diverse ecological contexts ([@B78]).

Human TAAR Isoforms
-------------------

In humans, TAAR genes are located on chromosome 6q23.2 ([@B13]; [@B15]) with six functional genes (TAAR1, TAAR2, TAAR5, TAAR6, TAAR8, and TAAR9) and three pseudogenes (TAAR3, TAAR4, and TAAR7) present ([@B80]). Function-modifying polymorphisms of TAAR1 ([@B115]), TAAR2 ([@B12]), TAAR6 ([@B33]; [@B102], [@B101]; [@B18]), and TAAR9 ([@B129]; [@B91]) have been reported. While such genetic variants have been suggested to have clinical relevance, reports have rarely been independently validated, and studies are often confined to rather small sample sizes, making firm conclusions of the putative clinical relevance difficult.

Endogenous TAAR Ligands
-----------------------

Although only TAAR1 has been officially de-orphanized ([@B2]), a number of endogenous ligands for individual TAAR isoforms have been identified, many of which are simply the decarboxylation products of amino acids. Notable endogenous ligands of individual TAARs are 2-phenylethylamine (PEA), *p*-tyramine (TYR), and tryptamine, all of which activate TAAR1, and probably also TAAR4; trimethylamine (TMA), a tertiary amine product of the microbial degradation of carnitine and choline, is a high affinity agonist at TAAR5; and as yet unidentified TAARs are activated by the diamines putrescine and cadaverine.

### 2-PEA and *p*-TYR

2-Phenylethylamine and *p*-TYR ([@B118]), as well as a number of other endogenous amines such as tryptamine ([@B118]), 3-iodothyronamine ([@B114]), and 3-methoxytyramine ([@B15]; [@B120]) are selective agonists at human TAAR1. PEA and TYR are the products of aromatic [L]{.smallcaps}-amino acid decarboxylase (AADC)-mediated decarboxylation of [L]{.smallcaps}-phenylalanine and [L]{.smallcaps}-tyrosine, respectively, with degradation occurring primarily *via* monoamine oxidase (**Figure [1](#F1){ref-type="fig"}**). Subsequent enzymatic conversion to a variety of other TAAR ligands such as *p*-octopamine, *N*-methylphenylethylamine, and *N*-methyltyramine is also possible (**Figure [1](#F1){ref-type="fig"}**). While PEA synthesis is often reported as being neuronal, AADC is also present in a number of non-neuronal tissues including epithelial cells of the gastrointestinal tract ([@B73]; [@B131]) and lungs ([@B73]; [@B82]). In addition, [L]{.smallcaps}-phenylalanine and [L]{.smallcaps}-tyrosine are readily decarboxylated by commensal prokaryotes ([@B86]; [@B59]; [@B135]) providing an additional pathway for the production of PEA and TYR in tissues that interface with the environment. Furthermore, dietary intake provides a third source of PEA and TYR in the gastrointestinal tract. Both compounds have long been recognized as being enriched in commonly ingested foods; with aged cheeses, red wine, chocolate, and fermented meats particularly well documented for their enriched levels of PEA and/or TYR ([@B25]). In general, any foods that involve anaerobic fermentation as part of their production can be expected to contain elevated levels of one or more trace amines ([@B126]; [@B47]; [@B106]). Indeed, the ability to detect increased levels of compounds such as TYR and PEA in microbe-contaminated foods may be one of the evolutionary driving forces for the appearance of TAARs in the olfactory epithelium. Seafood also provides a rich source of TYR and PEA, as well as other putative TAAR ligands ([@B3]; [@B11]). The potential of such dietary sources to lead to the activation of host TAARs, particularly in sensitive individuals, has only just begun to be recognized by those with research interests other than TAARs ([@B98]). All known endogenous ligands for TAARs are volatile, and have been identified in the urine and feces from a number of species. As such, inhalation of TAAR ligands associated with environmental sources is an additional source of trace amines in the pulmonary system.

![Schematic representation of trace amine synthetic and degradative pathways. 2-phenylethylamine and *p*-tyramine are primarily synthesized by decarboxylation of precursor amino acids *via* the enzyme aromatic [L]{.smallcaps}-amino acid decarboxylase. Depending on the cell type, [L]{.smallcaps}-phenylalanine can be converted into [L]{.smallcaps}-tyrosine *via* either tyrosine hydroxylase or a dedicated phenylalanine hydroxylase. Degradation of 2-phenylethylamine and *p*-tyramine is primarily *via* monoamine oxidase, 2-phenylethylamine being a highly selective substrate for the B isoform, whereas *p*-tyramine is a mixed monoamine oxidase-A and -B substrate. Both 2-phenylethylamine and *p*-tyramine can also be converted to a variety of other compounds that are also agonists at one or more TAAR. MAO, monoamine oxidase.](fphar-09-00680-g001){#F1}

Once synthesized, ingested, or inhaled, there appears to be no storage mechanism for either PEA or TYR in mammalian cells. The half-life for the endogenous pool is less than 30 s ([@B34]) indicating a very high turn-over rate with typical tissue concentrations being in the 1--10 ng/g tissue range, equating to approximately 10--100 nM ([@B7]). Release of TYR and PEA from neuronal preparations is dependent solely on the total tissue levels ([@B55]; [@B35]), consistent with a diffusion-mediated process and a lack of storage ([@B66]). We have confirmed ready diffusion of TYR across synthetic lipid bilayers ([@B10]), and in native membrane preparations this appears to be further enhanced by the presence of organic cation transporter 2 (OCT2; *Slc22A2*), a bidirectional facilitated diffusion transporter which exhibits a *K*~t~ for TYR of ≃100 nM ([@B9]). Taken together, these studies indicate that PEA and TYR readily cross cell membranes, a situation that means local levels of PEA and TYR exist in a steady state and are sensitive to fluctuations in synthesis and/or degradation.

### Trimethylamine

During the initial classification of TAARs as receptors involved in olfaction, TMA was identified as a potent, selective agonist at human TAAR5 ([@B79]), a finding that has subsequently been independently verified ([@B133]; [@B139]). Interestingly, there is no known mammalian pathway for the production of TMA. Rather, TMA synthesis appears to be due to the action of the constitutive microbiota on betaine, carnitine, and (phosphatidyl)choline ([@B26]; [@B142]; [@B67]). As such, TMA represents a good candidate molecule for involvement in microbe-host signaling cascades. Moreover, elevated TMA levels have been found to result from dysbiosis in the intestines, vagina, and oral cavity ([@B40]; [@B140]). Degradation of TMA occurs almost exclusively in the liver through the action of flavin monooxygenase 3 (FMO3) ([@B40]). This raises interesting pharmacokinetic questions since the site of degradation is relatively distant from the site of production, thus raising the possibility of tonic activation of any TAAR5 that is present between the two sites. Indeed, TMA has been identified as a constituent of numerous body fluids ([@B90]). This possibility is further strengthened when considering that the *K*~m~ of FMO3 for TMA is 28 μM ([@B72]), 100-fold in excess of the EC~50~ of TMA at human TAAR5 ([@B8]). Outside of the mammalian body, TMA production is associated with bacterial degradation of meat products, in particular fish ([@B56]).

### Cadaverine, Putrescine, and Other Polyamines

In experimental animals, the pan knockout of the TAAR2--TAAR9 cluster eliminates behavioral responses to the presence of cadaverine and putrescine ([@B29]). Furthermore, a number of teleost-specific TAAR isoforms are also activated by cadaverine ([@B57]) and other diamines ([@B77]). The relevance of these observations to human physiology is supported by the recent identification of a putative diamine-binding site in human TAAR6 and TAAR8 ([@B77]; [@B61]), which has been predicted *via in silico* analysis to bind cadaverine and putrescine ([@B61]).

Both putrescine and cadaverine are produced by the decarboxylation of precursor [L]{.smallcaps}-amino acids, ornithine *via* ornithine decarboxylase in the case of putrescine, and lysine *via* lysine decarboxylase in the case of cadaverine ([@B88]; [@B104]). Like other TAAR ligands, both are also produced by microbial action on proteinaceous materials, and as such are associated with decaying flesh. Indeed, putrescine and cadaverine are often credited with being the "smell of death."

Tissue and Cellular Distribution of TAARs
-----------------------------------------

One of the factors that has hampered the advancement of TAAR pharmacology has been a general lack of suitable reagents to probe the individual isoforms (see [@B8] for details). Basal expression levels of TAARs are generally very low, and only TAAR1 has been studied in detail. Indeed, TAAR1 is the only isoform for which a well-validated anti-human antibody has been described ([@B107]). With respect to the TAAR family in general, the most well-replicated finding has been the presence of all TAAR isoforms except TAAR1 in the olfactory epithelium, including in humans ([@B79]; [@B53]; [@B49]; [@B56]; [@B68]; [@B123]). In these olfactory systems, individual isoforms have been shown to respond to a variety of volatile amines associated with distinct ecological cues ([@B42]; [@B29]; [@B76]; [@B139]; [@B78]; [@B113]) including predator presence, spoiled food, and conspecifics of the opposite gender. In addition, individual TAARs are also expressed throughout the body, including both central nervous and peripheral organ systems ([@B8]).

### TAAR1

While TAAR1 is well established as being expressed throughout the brain of experimental animals, primarily associated with the major monoaminergic (in particular, although not exclusively, dopaminergic) nuclei and projection areas, few studies have attempted to confirm such findings in humans ([@B13]; [@B80]). It is likely that a similar distribution is present in humans, a situation supported by the observation of a normalization of functional magnetic resonance imaging (fMRI) in various brain regions, in particular those associated with the dopaminergic reward circuitry, by a mixed 5-HT~1A~/TAAR1 compound in patients with schizophrenia ([@B92]). Similar modifications of brain activity in response to a highly selective TAAR1 agonist had previously been reported using pharmacological MRI in rodent models ([@B109]). Expression of TAAR1 has also been reported to be present in the spinal cord of multiple species including humans ([@B13]; [@B81]; [@B50]), as well as in human astrocytes ([@B23]).

TAAR1 expression is also present in a number of nutrient sensing organs in humans, where it appears to regulate hormone secretion in response to nutrients ([@B1]; [@B107]). Specifically, TAAR1 has been confirmed to be present in pancreatic β-cells ([@B109]; [@B107]), D cells of the stomach ([@B1]; [@B107]), and enterochromaffin mucosal cells of the intestines ([@B69]; [@B107]). Expression in human leukocytes ([@B28]), including peripheral mononuclear (PMN) cells ([@B93]), B lymphocytes ([@B134]; [@B4]), monocytes ([@B4]), polymorphonuclear leukocytes ([@B4]), NK cells ([@B4]), and T lymphocytes ([@B4]; [@B121]), has also been established (**Table [1](#T1){ref-type="table"}**). Furthermore, methamphetamine-mediated stimulation of T lymphocytes has been reported to increase TAAR1 expression levels ([@B121]). Given that methamphetamine itself is a TAAR1 agonist ([@B15]; [@B118]), this raises the possibility of a positive feedback, amplification loop for TAAR1 signaling in T lymphocytes. Such a positive feedback loop has recently been described in response to the highly selective TAAR1 agonist RO5203648 in placental cells ([@B122]).

###### 

TAAR expression in human leukocyte populations.

  Receptor isoform   Immune cell type               Transcript or protein
  ------------------ ------------------------------ -----------------------------------
  TAAR1              Unspecified leukocytes         mRNA ([@B28])
                     Peripheral mononuclear cells   mRNA ([@B93])
                     B cells                        mRNA and protein ([@B4]; [@B121])
                     Monocytes                      mRNA ([@B4])
                     PML                            mRNA and protein ([@B4])
                     NK cells                       mRNA ([@B4])
                     T cells                        mRNA and protein ([@B4]; [@B121])
  TAAR2              Peripheral mononuclear cells   mRNA ([@B93])
                     B cells                        mRNA ([@B93]; [@B4])
                     Monocytes                      mRNA ([@B4])
                     PML                            mRNA and protein ([@B4])
                     NK cells                       mRNA ([@B4])
                     T cells                        mRNA ([@B4])
  TAAR5              Not present ([@B93])           
                     B cells                        mRNA ([@B4])
                     Monocytes                      mRNA ([@B4])
                     PML                            mRNA ([@B4])
                     NK cells                       mRNA ([@B4])
                     T cells                        mRNA ([@B4])
  TAAR6              Unspecified leukocytes         mRNA ([@B28])
                     B cells                        mRNA ([@B4])
                     Monocytes                      mRNA ([@B4])
                     PML                            mRNA ([@B4])
                     NK cells                       mRNA ([@B4])
                     T cells                        mRNA ([@B4])
  TAAR8              Unspecified leukocytes         mRNA ([@B28])
                     Not present ([@B4])            
  TAAR9              Unspecified leukocytes         mRNA ([@B28])
                     B cells                        mRNA ([@B4])
                     Monocytes                      mRNA ([@B4])
                     PML                            mRNA ([@B4])
                     NK cells                       mRNA ([@B4])
                     T cells                        mRNA ([@B4])

Notably, the available evidence indicates that TAAR1 resides primarily intracellularly in all tissues and cell types studied ([@B80]; [@B6]; [@B105]; [@B107]), only translocating to the plasma membrane following agonist-induced receptor heterodimerization ([@B37], [@B36]; [@B52]). Therefore, the ability of PEA and TYR to readily cross cell membranes either by diffusion ([@B10]), OCT2-mediated transport ([@B9]), or *via* other as yet unidentified transporters, is a critical first step in TAAR1 signaling cascades.

### TAAR2

TAAR2 is a little unusual, being the only family member with a gene containing more than one exon ([@B80]). Very little is known, however, about its distribution. In human leukocytes, there is some evidence that TAAR2 expression may mirror that of TAAR1, with TAAR2 mRNA reported in B lymphocytes, monocytes, NK cells, and T lymphocytes ([@B93]; [@B4]), and both mRNA and protein reported in granulocytes ([@B4]). The co-localization of TAAR1 and TAAR2 may be functionally important, with heterodimerization between the two having possible consequences to TAAR1 signaling ([@B4]). In laboratory rodents, TAAR2 mRNA has also been reported in duodenal mucosal cells ([@B60]), heart ([@B20]), and testis ([@B19]).

### TAAR5

Although there is a known ligand (TMA) identified that is well established to be present in humans, very few studies have investigated the expression profile of TAAR5. A potential preferential expression in human B lymphocytes has been suggested, with low level expression in other leukocyte populations ([@B4]). In rodents, TAAR5 mRNA is expressed in brain, with a distribution partially overlapping that of TAAR1 ([@B31]). Spinal cord ([@B50]) and testis ([@B19]) expression has also been suggested.

### TAAR6

In human brain, TAAR6 transcript levels may surpass those of TAAR1 ([@B33]), and also be primarily localized to known monoaminergic projection pathways including amygdala ([@B13]; [@B33]), basal ganglia ([@B33]), frontal cortex ([@B33]), hippocampus ([@B13]; [@B33]), and substantia nigra ([@B33]). Outside of the brain, TAAR6 transcripts have also been reported in kidney ([@B13]), and leukocytes ([@B28]; [@B4]). Although present in rat spinal cord ([@B50]), no transcripts were found in human ([@B33]).

### TAAR8

Astroglial TAAR8 transcripts have been reported to be increased following activation by lipopolysaccharide treatment ([@B27]). Elsewhere in the human brain, TAAR8 mRNA was reported to be present in the amygdala ([@B13]). [@B28] also reported TAAR8 transcripts in leukocytes, although this was not confirmed by others ([@B4]). Whether lipopolysaccharide activation of leukocytes increases TAAR8 levels as observed in astrocytes is unknown. Expression of TAAR8 in the kidney has also been suggested ([@B13]).

### TAAR9

All leukocyte populations studied have been reported to express TAAR9 ([@B28]; [@B4]), with human expression also suggested in the spleen ([@B108]), pituitary gland ([@B129]), and skeletal muscle ([@B129]).

TAARs and the Immune System
===========================

Overall, the evidence described above indicates that multiple TAARs are expressed in the immune system, in particular in various populations of leukocytes (**Table [1](#T1){ref-type="table"}**), and that in at least some cases, this is regulated in response to leukocyte activation. This raises the possibility that TAARs and their ligands may comprise a hitherto unsuspected target for modulation of immune function. Furthermore, given the ready production of such ligands by members of the constitutive microbiota, a role for TAARs in microbiota-immune system signaling should be considered. In the following sections, we will review the current state of the knowledge of the effects of TAARs on leukocyte function, developing a model whereby TAARs are considered as potential therapeutically relevant targets in disorders associated with dysregulated immune responses to environmental factors. In particular growing evidence indicates TAARs may be attractive novel molecular targets in inflammatory bowel disease (IBD).

TAARs Regulation of Leukocyte Function
--------------------------------------

As described above, TAARs are differentially expressed between various leukocyte populations in humans. Notably, both TAAR1 and TAAR2 expression are increased following leukocyte activation ([@B93]; [@B134]). The endogenous TAAR1 ligands PEA and TYR are chemotactic for PMN ([@B4]), and can be released from activated platelets ([@B28]). It is not known if TAAR1 ligands are chemotactic for other leukocyte populations and this is an area for future study. This chemotactic response is dependent on the expression of both TAAR1 and TAAR2, possibly due to agonist-induced heterodimerization ([@B4]), similar to that also reported between TAAR1 and D~2~-like dopamine receptors (D2R) ([@B36]; [@B52]).

Activation of leukocyte TAAR1 may also regulate T helper (Th) cell differentiation, directing this away from the Th1 phenotype and toward the Th2 phenotype. Supporting this, a TAAR1-dependent increase in interleukin (IL)-4 secretion, decrease in IL-2 secretion, and decrease in expression of secreted phosphoprotein 1 have been reported ([@B4]). Promotion of the Th2 phenotype would be expected to lead to increased activation of B lymphocytes, and TAAR1 agonists do increase B cell secretion of immunoglobulin E (IgE) ([@B4]). TAAR1-mediated B lymphocyte apoptosis has also been reported ([@B134]). Importantly, all of the above effects of TAAR1 agonists occur with low nanomolar EC~50~ values, well within the range of endogenous TA plasma levels ([@B28]). In healthy individuals, PEA and TYR levels are tightly controlled. As previously described the endogenous pool exists in a steady state, with no storage and a half-life of less than 30 s ([@B34]). As such, it is possible that alterations in TAAR1 signaling can occur simply due to fluctuations in PEA and/or TYR levels, and such altered signaling could affect homeostatic immune responses.

In recent years, it has become increasingly apparent that leukocyte populations are also regulated by receptors commonly associated with neurotransmission ([@B100]). In particular, dopamine and its receptors have been shown to be present in various populations including B lymphocytes, dendritic cells, neutrophils, NK cells, and T lymphocytes ([@B100]), and to play a role in signaling between immune cells ([@B100]; [@B103]). Activation of individual dopamine receptors has been shown to be involved in both B lymphocyte ([@B103]) and T lymphocyte activation ([@B100]), T lymphocyte cytokine secretion and migration ([@B100]), and dependent on the dopamine receptor sub-type activated promotion of Th1, Th2, or Th17 differentiation ([@B100]). Since TAAR1 has been established as an endogenous modulator of D2R, TAAR-mediated regulation of dopaminergic signaling within immune cells may also occur, and is perhaps likely. In particular, TAAR1 appears to function as an endogenous rheostat, maintaining homeostasis of dopaminergic systems ([@B14]; [@B109]) by selectively heterodimerizing with D2R ([@B37], [@B36]; [@B110]; [@B52]). In the central nervous system, this TAAR1 agonist-induced heterodimerization causes biased signaling involving the G protein-independent β-arrestin cascade ([@B36]; [@B52]). Intriguingly, β-arrestin isoforms have been implicated in autoimmune disorders due to regulation of both innate and adaptive immune system functions, including chemotaxis ([@B64]), gating cytokine receptor responsitivity ([@B51]), Th cell differentiation ([@B64]), epithelial cell barrier functions ([@B64]), and inflammation-induced epithelial cell apoptosis ([@B137]). Therefore, the potential of TAAR1 to regulate D2R signaling *via* the β-arrestin cascade in leukocytes warrants parallel systematic investigation alongside the effects of TAAR1 agonists alone.

TAARs and the Major Histocompatibility Complex
----------------------------------------------

The major histocompatibility complex (MHC) is a critical mediator of T lymphocyte activation. Degradation and presentation of antigens on either class I or class II MHC by antigen-presenting cells, such as dendritic cells or macrophages, is essential for activation of CD8+ and CD4+ T cells, respectively. Interaction of CD8+ T lymphocytes with the peptide--MHC-I complex, along with the involvement of Th cells, causes these cells to differentiate into cytotoxic T lymphocytes (CTL) that can induce the lysis of infected or altered cells. Interaction of CD4+ Th cells with the peptide--MHC-II complex induces their activation. In addition, the context provided by cytokines in the extracellular environment following release from damaged, infected, or otherwise altered cells present in the microenvironment further influences the specific differentiation of CD4+ T cells into the various Th subsets including Th1, Th2, Th17, and Treg. Intriguingly, TAARs were recently implicated in the recognition of class I MHC, at least in the context of MHC-mediated mate selection ([@B113]). Here, the TAAR3 genotype was shown to play a role in female selection of MHC-diverse males by the greater sac-winged bat. While the context of this detection is not immune cell responsitivity, and TAAR3 is a pseudogene in humans, this does indicate that the possibility of TAARs involvement in MHC-mediated responses within leukocytes should be considered, and warrants further study.

TAARs and Their Ligands in IBD
------------------------------

Inflammatory bowel disease comprises a group of chronic inflammatory disorders, where Crohn's disease (CD) and ulcerative colitis (UC) are the two major forms. The etiology of IBD involves complex multifactorial components including genetic, immunologic, and environmental influences ([@B70]; [@B71]; [@B141]) that remain to be fully elucidated. Key components of the immune response in IBD include increased leukocyte recruitment to the gastrointestinal mucosa ([@B132]) involving both innate and adaptive immune systems, and loss of homeostatic control of Th cell differentiation into Th1 ([@B45]; [@B100]; [@B141]), Th17 ([@B74]; [@B100]; [@B141]), and Treg ([@B100]; [@B141]) phenotypes. Normalization of epithelial cell--immune system communication ([@B65]; [@B87]) and identification of molecules that mediate leukocyte chemotaxis ([@B125]; [@B5]) are regarded as promising therapeutic targets. As described above, TAAR1-mediated signaling, either direct or through modulation of D2R, may regulate all these responses. Furthermore, microbial production of trace amines is also implicated in the ability of microbes to adhere to epithelial cells, and in subsequent internalization of microbes and epithelial cell cytokine production ([@B41]; [@B83]).

Among the most prominent environmental influences in IBD are a decreased complexity of the constitutive microbiota ([@B45]; [@B70]; [@B71]) and various dietary factors ([@B70]; [@B75]; [@B71]; [@B117]; [@B141]). The presence of TAARs in almost all leukocyte populations, and the availability of their ligands from intestinal epithelial cells, the microbiota, and food, indicates that the trace aminergic system is conveniently positioned at the interface of genetics, leukocyte chemotaxis and activation, microbiota, and diet (**Figure [2](#F2){ref-type="fig"}**). The putative involvement of TAARs in IBD, however, has not previously been systematically addressed or formally hypothesized.

![Schematic diagram of hypothetical interactions between trace amines (TA) and the mucosal epithelial layer immune system. TA levels can increase due to an increased activity of aromatic [L]{.smallcaps}-amino acid decarboxylase (AADC) in intestinal epithelial cells, or by exogenous sources including food, microbial activity, decaying animals, or in secretions such as urine, sweat, or breath. In humans, trimethylaminuria \[fish (mal)odor syndrome\] increases the secretion of TMA. TA cross lipid bilayers, including both the apical and basolateral surfaces of the intestinal epithelium, by a combination of simple diffusion and transporter-mediated facilitated diffusion. The overarching hypothesis illustrated is that pathological accumulation of TA in the basolateral compartment may (a) recruit immune cells to the area and/or (b) induce the differentiation of T cells to promote inflammation and subsequent damage to the epithelium. Dashed orange lines indicate movement of TA, dashed blue lines indicate movement of immune cells, and the balance beams indicate a potential TA-induced shift in the balance of T helper cell phenotypes. MALT, mucosal-associated lymphoid tissue; DC, dendritic cell.](fphar-09-00680-g002){#F2}

Changes in trace amine metabolism have recently been correlated to both IBD disease status ([@B136]; [@B112]) and the decreased microbiota complexity that is a defining characteristic of IBD ([@B112]). Unbiased metabolomic screens have directly implicated dysregulation of known TAAR ligands in the pathology of IBD, although the presence of high affinity receptors for these compounds has been overlooked. Most notably, PEA has been reported to be increased in fecal samples from CD patients, and to be one of the metabolites that allows discrimination of CD from healthy patient populations ([@B62]; [@B112]). Such results are also consistent with previous studies identifying altered tyrosine and phenylalanine metabolism as a factor for discriminating IBD from healthy populations ([@B16]; [@B63]). Putrescine and cadaverine have also been identified as selectively elevated in CD patients ([@B112]) consistent with previous reports of altered lysine metabolism ([@B85]). Likewise, in UC patients, significant elevations in TYR and cadaverine have been reported ([@B112]). Furthermore, elevated levels of fecal TMA have been reported in IBD ([@B85]), along with both elevations and reductions of its primary metabolite trimethylamine-*N*-oxide (TMAO) ([@B136]; [@B112]).

Despite these identified changes in TAAR ligands, there appears to be only a single study that has identified possible roles of TAARs in IBD ([@B124]). Here, in an unbiased microarray screen, TAAR2, TAAR5, and TAAR9 were found to be among the most highly upregulated genes in biopsies from inflamed regions of CD patients, and contributed to the separation of CD patients from those with irritable bowel syndrome ([@B124]). Although neither PEA nor TYR are agonists at TAAR2, the aforementioned heterodimerization of TAAR2 with TAAR1 could provide a link between the altered TYR and PEA metabolomic profiles and TAAR2 over-expression, both of which allow discrimination of IBD populations. It is also worth noting that activity-modifying polymorphisms of D2R have been implicated in CD ([@B84]). As such, given the well-documented role of TAAR1 in normalizing D2R signaling, even in the absence of *de facto* changes in TAAR1 or its endogenous ligands, it may still be a viable target for pharmacotherapy. Importantly in this aspect, TAAR1-directed therapeutics have been confirmed in phase I clinical trials to be generally safe ([@B44]).

A TAAR-centric Hypothesis of IBD
--------------------------------

Based on the above evidence, we hypothesize that altered trace amine homeostasis can result in hyperactivity of the immune system which clinically can manifest as IBD. Such loss of homeostasis can occur through many different mechanisms. For example: polymorphisms of one or more TAAR resulting in altered leukocyte homeostasis; changes to trace amine levels as a result of altered synthesis and/or degradation; or altered trace amine load due to microbial action, diet, or altered trace amine transport properties. Such altered levels can then result in changes in chemotaxis and/or activation of leukocytes, and/or TA-induced changes in the ability of members of the microbiota to adhere to and penetrate the epithelial cell layer. Furthermore, in situations with primary dysbiosis, alterations of trace amine production by the constitutive microbiota could easily manifest, which may lead to loss of homeostasis of leukocyte chemotaxis and activation and/or increased sensitivity to foods containing trace amines or their precursors.

A Role for TAARs in Immune Disorders of Other Organ Systems
-----------------------------------------------------------

In addition to a putative role for TAARs in gastrointestinal immune system dysfunction, coordination between the host immune system, epithelial cells, and the constitutive microbiota needs to occur and be tightly controlled in many other situations. In particular, a similar complex trilateral communication network is present in the pulmonary and urogenital systems, and a similar role for the trace aminergic system could occur in each of these. Furthermore, a role for dysregulated immune systems in neurologic and psychiatric disorders is becoming increasingly recognized. With few studies available, firm links in each of these systems requires a great deal more foundational work.

### The Pulmonary System

In recent years, there has been a growing appreciation of possible links between pulmonary hypersensitivity disorders such as environmentally induced asthma, and dysbiosis ([@B30]; [@B54]), including gastrointestinal dysbiosis ([@B111]; [@B138]). We are unaware of any studies directly implicating an altered trace amine metabolome with lung inflammation at this point in time, but the fact that all known endogenous TAAR ligands are highly volatile and present in a wide range of environmental contexts including food and animal urine and feces, while their receptors appear to play a role in regulating leukocyte chemotaxis and activation, suggests a putative link that warrants consideration. It is also worth noting that polymorphism of TAAR6 has been linked to corticosterone responsiveness in asthma patients ([@B18]). Corticosterone is not known to be a ligand for any TAAR, suggesting that TAAR6 may be contributing in an indirect manner.

### The Urogenital Tract

Trimethylamine is sexually dimorphic in mice ([@B48]), and urinary levels are also reported to be increased in humans during menstruation ([@B89]) possibly due to a sex hormone-induced regulation of its degradation ([@B24]; [@B116]). The socially stigmatizing odor associated with vaginal dysbiosis is largely a function of increased TMA levels ([@B40]; [@B140]). The production of putrescine, cadaverine, and TYR have been identified as important virulence factors in the progression of the dysbiotic environment ([@B95]) and may underlie the increased incidence of bacterial vaginosis among smokers ([@B94]).

### The Nervous System

An inflammatory component to, at least, some neurological disorders is now recognized, and trace amines are synthesized in neurons, and then immediately released to the extra-neuronal environment by diffusion mediated events. Such released trace amines may recruit and activate leukocytes if the homeostatic equilibrium between synthesis and degradation is lost. While this is merely theoretical at this time, polymorphism of TAAR1 has been linked to fibromyalgia sensitivity ([@B119]), and fibromyalgia may involve an immune system component.

#### The central nervous system in IBD

Estimates suggest that upward of 33% of IBD patients report coincidence of non-gastrointestinal symptoms ([@B17]; [@B32]), and such symptoms may even precede gastrointestinal symptomatology. While neuropsychiatric complications are rare, IBD patients do show an increased risk of cerebrovascular disorders such as stroke ([@B32]; [@B96]). IBD is also associated with upto a five-fold increase in demyelinating disorders such as multiple sclerosis that is independent of immunosuppressant therapy, and which may be related to a generalized loss of T lymphocyte homeostasis ([@B17]; [@B32]). Even though the role of TAARs have not been investigated with respect to demyelination, TAARs may be a future novel target for control of neuroinflammation given the increasing evidence for a putative role in regulating immune cell function and TAARs expression throughout the brain.

#### Inflammation in central nervous system disorders

There is an increasing interest in the "gut--brain axis," with signals originating in the gastrointestinal tract, including from the constitutive microbiota, now accepted as regulating central nervous system function ([@B46]; [@B127]). Likewise, the association of low-grade inflammation with both increased risk of neuropsychiatric disorders and poor treatment outcomes is increasingly recognized ([@B99]). Such inflammation can be associated with both the central and peripheral nervous systems and non-neural tissues such as epithelial cells ([@B21]; [@B97]), and has been identified as a novel therapeutic target ([@B99]). Schizophrenia and bipolar disorder have both been reported to be associated with an increased prevalence of gastrointestinal disturbances, including increased inflammation and a dysfunctional epithelial barrier layer ([@B97]). Interestingly, a decrease in the constitutive microbiota diversity may also be associated with psychiatric disorders ([@B97]).

TAAR1 ligands are already in active development as treatments for neuropsychiatric disorders ([@B8]), and their potential to also modulate hyperactive immune function could offer an additional benefit. Of particular note is the spectrum of syndromes associated with chromosome 22q11.2 deletion that includes altered T lymphocyte differentiation resulting in hyper-reactive responses to environmental stimuli, and a marked increased risk of schizophrenia ([@B130]). One of the genes located to 22q11.2 is catechol-*O*-methyltransferase, which catalyzes the conversion of dopamine and norepinephrine to 3-methoxytyramine and normetanephrine, both of which are potent TAAR1 agonists. As such chromosome 22q11.2 deletion likely leads to a deficit in basal TAAR1 signaling.

The role of inflammation and the constitutive microbiota in neuropsychiatric indications is an emerging area. One specific aspect that is unresolved is whether neuroinflammation results from infiltration of peripheral leukocytes in to the central nervous system due to a dysfunctional blood--brain barrier, activation of the central immune cells such as microglia, or a combination of both. With highly selective TAAR ligands becoming established as a way to normalize central neuronal function, the putative ability of the same compounds to normalize factors that regulate inflammatory effects would be a considerable advantage over existing therapeutics. As described in preceding sections, there is growing evidence that TAARs also play a role in regulating endothelial cell barrier functions and inflammatory responses in the gastrointestinal system, and possibly also in the placenta ([@B122]). Whether such effects also occur within the central nervous system is a key area for future systematic investigation. As far as we are aware, the TAAR expression profile of microglia and endothelial cells of the blood--brain barrier have not yet been examined.

Concluding Statements
=====================

The trace aminergic system is an emerging target for pharmacotherapy that is garnering increasing interest. We propose that in addition to neurological/psychiatric and metabolic disorders, there is increasing evidence to support a putative role in environmental hypersensitivity immune system disorders, in particular IBD, and that a systematic investigation of the role of TAARs and their ligands in leukocyte homeostasis is warranted. We believe that such a putative role has an evolutionary basis. TAAR1, while evolutionarily the oldest family member, is the only isoform that is not involved in olfaction. This suggests that either this function has been lost in all species from the cartilaginous fish upward, or that co-opting TAARs to the olfactory epithelium following a gene duplication event offered an evolutionary advantage. Given that TAAR1 is under strong negative selection pressures, and that the second oldest family member, TAAR4, shares ligand selectivity with TAAR1, we believe this latter option is the most likely. The ability to detect compounds in the environment that can also trigger immune responses, and where that detection induces an innate avoidance response (as is known to occur), would offer a considerable advantage in protecting the organism from ingesting microbial contaminated foods that could be potentially injurious or even fatal. The fact that these compounds are also excreted in urine and feces due to intestinal microbiota metabolism of ingested meat, offers an additional advantage of triggering avoidance of areas associated with potential predators. It is also interesting to note that many aquatic species show an innate avoidance response to parasites and parasite-infected conspecifics, a response that is almost indistinguishable from their avoidance of predators. The chemical basis of this response is unknown, and TAARs could represent a new possibility for the molecular basis of such responses.

In conclusion, there is growing evidence that the trace aminergic system plays a role in the complex tripartite communication web between the epithelial cells that form a barrier between the host and the environment, host immune cells, and the constitutive microbiota, and that loss of trace amine homeostasis can be associated with immune system hyper-reactivity toward environmental cues.
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